Literature DB >> 27407880

Evaluation of Suspected Monoclonal Gammopathies: Experience in a Tertiary Care Hospital.

G S Chopra1, P K Gupta2, D K Mishra3.   

Abstract

BACKGROUND: Monoclonal gammopathies occurs in patients with malignant diseases of plasma cells and lymphocytes and in few benign conditions. The objective of this study was to assess the precision, accuracy and confirmation of monoclonal gammopathies on serum protein electrophoresis (SPE) and the clinical relevance of detection and characterization of M component.
METHODS: All samples received for serum electrophoresis in the last 3 years were analysed for data on M band positivity and correlating it with clinical profile of the patients. Immunofixation (IFE), Immunoelectrophoresis (IEP) and IgG, IgM estimation were carried out in few cases. The follow up of cases was done by serial monitoring of SPE and β2 microglobulin levels.
RESULTS: 1155 samples were received during the 3 years period. 282 (24.4%) samples were positive for M component on SPE. Of these, 239 (84.8%) patients had M spike in λ region and 43 patients had M spike in β region. The mean load of the M protein band in the λ region was 37.8% and in β region was 35.8%. IgG with κ chain was seen in 40%, IgG with λ chain was seen in 50%, 5% patients each had IgM with κ and IgA with λ light chain. 246 samples (96.5%) had high levels of β2 microglobulin. Of the 116 cases of multiple myeloma, IgG levels was more commonly raised (5%) as compared to IgA (6.9%) and IgM (5.2%).
CONCLUSION: It is recommended that SPE should be performed in patients having unexplained weakness, anaemia, back pain, osteoporosis, osteolytic lesions, fractures, renal insufficiency or recurrent infections.

Entities:  

Keywords:  Electrophoresis; M band; Multiple myeloma; Serum protein

Year:  2011        PMID: 27407880      PMCID: PMC4921976          DOI: 10.1016/S0377-1237(06)80055-9

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  13 in total

1.  Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.

Authors:  J Cuzick; B L De Stavola; E H Cooper; C Chapman; I C MacLennan
Journal:  Br J Haematol       Date:  1990-08       Impact factor: 6.998

2.  Strategy to diagnose monoclonal gammopathies in serum: high-resolution electrophoresis, immunofixation, and kappa/lambda quantification.

Authors:  D F Keren; J S Warren; J B Lowe
Journal:  Clin Chem       Date:  1988-11       Impact factor: 8.327

3.  Multiple myeloma: beta-2-microglobulin is not a useful follow-up parameter.

Authors:  M Boccadoro; P Omedè; R Frieri; S Battaglio; G Gallone; M Massaia; V Redoglia; A Pileri
Journal:  Acta Haematol       Date:  1989       Impact factor: 2.195

4.  Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders.

Authors:  H Garewal; B G Durie; R A Kyle; P Finley; B Bower; R Serokman
Journal:  J Clin Oncol       Date:  1984-01       Impact factor: 44.544

5.  The clinical aspects of biclonal gammopathies. Review of 57 cases.

Authors:  R A Kyle; R A Robinson; J A Katzmann
Journal:  Am J Med       Date:  1981-12       Impact factor: 4.965

6.  A new staging system for multiple myeloma based on the number of S-phase plasma cells.

Authors:  J F San Miguel; R García-Sanz; M González; M J Moro; J M Hernández; F Ortega; D Borrego; M Carnero; F Casanova; R Jiménez
Journal:  Blood       Date:  1995-01-15       Impact factor: 22.113

7.  Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.

Authors:  T T Pelliniemi; K Irjala; K Mattila; K Pulkki; A Rajamäki; A Tienhaara; M Laakso; R Lahtinen
Journal:  Blood       Date:  1995-02-01       Impact factor: 22.113

8.  Diagnosis of multiple myeloma.

Authors:  Robert A Kyle
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

9.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

Review 10.  Monoclonal gammopathies: new approaches to clinical problems in diagnosis and prognosis.

Authors:  P R Greipp
Journal:  Blood Rev       Date:  1989-12       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.